Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GSK American Depositary Shares Representing 2 Ordinary Shares GSK

Consumer Cyclical
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with... see more

Recent & Breaking News (NYSE:GSK)

Trial Data, Recommendation, Manufacturing & Distribution Approval, and Recruitment Support Breakthrough Treatments - Research Report on Novo Nordisk, Novartis, GSK, Sanofi, and Neurocrine Biosciences

PR Newswire July 4, 2013

100 GlaxoSmithKline employees embark on global and local long-term volunteer assignments

PR Newswire June 26, 2013

Breakthrough Therapy Designation Status, Top-Line Results, and Business Proposals Boost Long-Term Growth in Pharmaceutical Companies - Research Report on Novartis, AstraZeneca, GSK, Sanofi, and Rigel

PR Newswire June 26, 2013

The Zacks Analyst Blog Highlights:GlaxoSmithKline, Biogen, Santarus, Novo Nordisk and Tetra Tech

PR Newswire June 20, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CSIQ, GSK, KSS and LMT

Accesswire June 18, 2013

Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline

PR Newswire June 12, 2013

GSK, AZN, KERX, and RPTP Early Briefing and Review

Accesswire June 7, 2013

Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products

Business Wire June 3, 2013

Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec, GlaxoSmithKline, Viropharma, and Celsion

PR Newswire May 31, 2013

Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist(TM) (trametinib) tablets, approved by FDA as single-agent therapies

PR Newswire May 29, 2013

From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers

Business Wire May 21, 2013

BREO(TM) ELLIPTA(TM) gains US approval for the treatment of COPD

PR Newswire May 10, 2013

BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD

Marketwired May 10, 2013

GSK, AZN, KERX, and RPTP Early Briefing and Review

Accesswire May 2, 2013

GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results

PR Newswire April 24, 2013

GlaxoSmithKline, Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

PR Newswire April 17, 2013

GlaxoSmithKline Issues Call for Applications Totaling $400,000 in GSK IMPACT Awards

PR Newswire April 17, 2013

GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today

PR Newswire April 6, 2013

GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive

PR Newswire April 5, 2013

Today's Technical View on AstraZeneca, GlaxoSmithKline, PDL BioPharma, and Herbalife

PR Newswire April 1, 2013